Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17387025 | 0.91 | GABRG2 (0.30) | GABRG2GABRB3GABRA2 | |
| SCHEMBL17386796 | 0.91 | — | — | |
| SCHEMBL17387281 | 0.88 | — | — | |
| SCHEMBL17387013 | 0.86 | — | — | |
| SCHEMBL17415917 | 0.86 | GABRG2 (0.30) | GABRG2GABRB3GABRA2 | |
| SCHEMBL17386991 | 0.86 | — | — | |
| SCHEMBL17386839 | 0.84 | — | — | |
| SCHEMBL17387154 | 0.84 | CRHR1 (0.30) | — | |
| SCHEMBL17387374 | 0.83 | — | — | |
| SCHEMBL17387221 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005864-B2 | Metallocene compound, catalyst for olefin polymer, method for producing olefin polymer, and olefin polymer | JAPAN POLYETHYLENE CORPORATION (JP) | 2018-06-26 | — | — | US | disclosed |
| EP-3078670-B1 | METALLOCENE COMPOUND, CATALYST FOR OLEFIN POLYMER, METHOD FOR PRODUCING OLEFIN POLYMER, AND OLEFIN POLYMER | JAPAN POLYETHYLENE CORP (JP) | 2017-12-27 | — | — | EP | disclosed |
| US-20170320981-A1 | METALLOCENE COMPOUND, CATALYST FOR OLEFIN POLYMER, METHOD FOR PRODUCING OLEFIN POLYMER, AND OLEFIN POLYMER | JAPAN POLYETHYLENE CORPORATION (JP) | 2017-11-09 | — | — | US | disclosed |
| US-9783625-B2 | Metallocene compound, catalyst for olefin polymer, method for producing olefin polymer, and olefin polymer | JAPAN POLYETHYLENE CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| EP-3078670-A1 | METALLOCENE COMPOUND, CATALYST FOR OLEFIN POLYMER, METHOD FOR PRODUCING OLEFIN POLYMER, AND OLEFIN POLYMER | Japan Polyethylene Corporation (JP) | 2016-10-12 | — | — | EP | disclosed |
| US-20160009838-A1 | METALLOCENE COMPOUND, CATALYST FOR OLEFIN POLYMER, METHOD FOR PRODUCING OLEFIN POLYMER, AND OLEFIN POLYMER | JAPAN POLYETHYLENE CORPORATION (JP) | 2016-01-14 | — | — | US | disclosed |
| EP-2963045-A1 | METALLOCENE COMPOUND, CATALYST FOR OLEFIN POLYMER, METHOD FOR PRODUCING OLEFIN POLYMER, AND OLEFIN POLYMER | Japan Polyethylene Corporation (JP) | 2016-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320981-A1 | METALLOCENE COMPOUND, CATALYST FOR OLEFIN POLYMER, METHOD FOR PRODUCING OLEFIN POLYMER, AND OLEFIN POLYMER | CPNE4, PIN4, PIN1 | GABRG2 4658/4885GABRB3 4779/4885GABRA2 4625/4885 |
| US-20160009838-A1 | METALLOCENE COMPOUND, CATALYST FOR OLEFIN POLYMER, METHOD FOR PRODUCING OLEFIN POLYMER, AND OLEFIN POLYMER | CPNE4, ALOX12, PIN1 | GABRG2 4629/4885GABRB3 4836/4885GABRA2 4667/4885 |
| US-10005864-B2 | Metallocene compound, catalyst for olefin polymer, method for producing olefin polymer, and olefin polymer | CPNE4, PPOX, PIN1 | GABRG2 4451/4885GABRB3 4657/4885GABRA2 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.